MMedXYNews
Ask AIHomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY News/Hematology-Oncology

Section

Hematology-Oncology

578 articles

Ask AI
All specialtiesHematology-OncologynewsClinical UpdatesCardiologyOncology

Latest updates

Allergy & Immunology

Divergent Roles of IL-12p40 and IL-18 in Severe Fibrosing Chronic Graft-versus-Host Disease: Implications for Immunity and Post-Transplant Outcomes

This study reveals distinct clinical associations of IL-12p40 and IL-18 in severe fibrosing chronic graft-versus-host disease, highlighting their differing impacts on relapse risk, survival, and immune responses post-allogeneic stem cell tr

Aug 27, 2026Sign in to read
Hematology-Oncology

Navigating the Decision-Making Burden in Cancer Care: Oncologists’ Perspectives and Strategies

This article explores how oncology clinicians perceive and manage the burden patients face when involved in treatment decisions, highlighting varied clinician approaches to balance patient autonomy with emotional support in shared decision

Aug 27, 2026Sign in to read
Hematology-Oncology

Epstein-Barr Virus Reactivation and PTLD in Pediatric Haploidentical HSCT: Incidence, Risks, and Clinical Outcomes

This study analyzes EBV infection and PTLD incidence in pediatric haploidentical HSCT, identifying prior CAR-T therapy, CMV viremia, and TBI conditioning as significant risk factors, with implications for enhanced monitoring and preemptive

Aug 27, 2026Sign in to read
Hematology-Oncology

Targeting ITK with Soquelitinib: A Promising Phase 1 Trial in Relapsed/Refractory T Cell Lymphomas

A phase 1 trial of soquelitinib, a selective ITK inhibitor, showed favorable safety and encouraging efficacy with Th1-skewing immunomodulation in relapsed/refractory peripheral T cell lymphomas, highlighting a novel therapeutic approach.

Aug 27, 2026
Hematology-Oncology

Distinct Myeloid Landscapes Define Prognostic Niches in Extranodal NK/T-Cell Lymphoma

Spatial multimodal profiling reveals two macrophage-defined ENKTL subgroups with distinct tumor-myeloid interactions influencing prognosis and potential immunotherapy targets.

Aug 27, 2026Sign in to read
Hematology-Oncology

Discovery of a Novel B-ALL Subtype Defined by IGH::FENDRR Rearrangement and KRAS Mutations With Poor Chemotherapy Response

A novel B-cell acute lymphoblastic leukemia subtype characterized by IGH::FENDRR rearrangement and KRAS mutations shows distinct molecular features and poor response to standard chemotherapy, highlighting the need for early immunotherapy an

Aug 27, 2026
Gastroenterology

Fecal Microbiota Transplantation: A Promising Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

This retrospective multicenter study evaluates fecal microbiota transplantation (FMT) for steroid-refractory acute graft-versus-host disease (aGvHD), demonstrating a 60.5% response at day 28 and highlighting FMT’s potential as a safe

Aug 27, 2026Sign in to read
Hematology-Oncology

Immunosenescence as a Key Barrier to CD19 CAR T-Cell Therapy in Chronic Lymphocytic Leukemia

This article explores how T-cell immunosenescence impairs the efficacy of CD19 CAR T-cell therapy in chronic lymphocytic leukemia, highlighting potential therapeutic strategies to overcome this barrier.

Aug 27, 2026
Hematology-Oncology

TP53-Mutated Clonal Hematopoiesis Drives Pro-Inflammatory Phenotype and Predicts Poor Outcomes After CAR T-Cell Therapy

TP53-mutant clonal hematopoiesis in CAR T-cell recipients is linked to a pro-inflammatory state, cytopenias, and worse survival, highlighting the importance of tailored monitoring strategies in this high-risk group.

Aug 26, 2026Sign in to read
Hematology-Oncology

Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis

The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients

Aug 25, 2026
Clinical Updates

Epidemiologic Insights into Transfusion-Related Alpha-Gal Syndrome: Risk Stratification and Clinical Implications

This review synthesizes key epidemiologic evidence linking transfusion-related allergic reactions with alpha-gal syndrome (AGS), revealing significant risk in blood type O recipients of B or AB plasma/platelets in AGS-endemic regions.

Aug 24, 2026Sign in to read
Hematology-Oncology

Comparative Outcomes of Treosulfan- versus Busulfan-Based Clofarabine Reduced Intensity Conditioning Regimens in Adult Allogeneic Transplant for Myeloid Malignancies

This retrospective study compares treosulfan and busulfan combined with clofarabine as reduced intensity conditioning before allogeneic transplant in adults with myeloid malignancies, highlighting faster neutrophil recovery and improved sur

Aug 24, 2026
Hematology-Oncology

Reassessing Total Body Irradiation in Young Children with ALL: Long-Term Safety and Outcomes

A French longitudinal study finds no increased long-term complications or compromised quality of life in children under 4 years undergoing TBI-based HSCT for acute lymphoblastic leukemia, challenging prior age restrictions.

Aug 24, 2026
Hematology-Oncology

Unveiling a Novel Fusion circRNA Regulating Mitochondrial Metabolism in t(4;11) B-cell Acute Lymphoblastic Leukemia

A newly identified KMT2A::AFF1-derived fusion circular RNA (AK_7_3) modulates mitochondrial metabolism and apoptosis in t(4;11) B-ALL, revealing potential therapeutic targets for this high-risk leukemia subtype.

Aug 24, 2026
Hematology-Oncology

Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay

This study demonstrates that detection of circulating tumor DNA (ctDNA) after treatment in large B-cell lymphoma predicts progression-free survival, highlighting the clinical utility of a rapid immunoglobulin rearrangement-targeted assay fo

Aug 24, 2026Sign in to read
Hematology-Oncology

Dual HLA-Restricted TCR-Engineered T Cells Targeting Cathepsin G: A Novel Approach for Effective AML Eradication

This study demonstrates that T cells engineered with a dual HLA-restricted TCR against cathepsin G effectively and safely eradicate AML cells, offering a promising immunotherapy for a broad AML patient population.

Aug 24, 2026
Hematology-Oncology

Integrating Genetics and Measurable Residual Disease to Optimize Therapy in Philadelphia Chromosome-Negative Adult ALL

Combining genetic risk stratification with measurable residual disease enables precise treatment allocation in adult Philadelphia chromosome-negative acute lymphoblastic leukemia, improving survival outcomes and guiding the use of allogenei

Aug 24, 2026Sign in to read
Hematology-Oncology

Oral Anticoagulation Significantly Lowers Venous Thromboembolism Rates in Ovarian Cancer Patients on First-Line Chemotherapy: Insights from a Quality Improvement Project

A quality improvement initiative integrating oral anticoagulants reduced venous thromboembolism incidence in ovarian cancer patients undergoing first-line chemotherapy without increasing bleeding risks.

Aug 24, 2026
Hematology-Oncology

ATG Versus ATG Plus Post-Transplant Cyclophosphamide: A Pilot Trial for GvHD Prophylaxis in Matched Donor Hematopoietic Cell Transplants

A randomized pilot trial shows comparable survival and safety outcomes for anti-thymocyte globulin alone versus combined with post-transplant cyclophosphamide, supporting further phase III investigation for graft-versus-host disease prophyl

Aug 24, 2026Sign in to read
Clinical Updates

Response Kinetics Following CAR T-Cell Therapy for Large B-Cell Lymphoma: Insights from the LYSA DESCAR-T Registry

This review synthesizes real-world data from the DESCAR-T registry on CAR T-cell therapy response kinetics in large B-cell lymphoma, highlighting the prognostic impact of early response patterns and factors influencing conversion from parti

Aug 24, 2026
Previous
9 / 25
1…7891011…25
Next

Most read

  1. 01Hematology-Oncology

    Precision Immunotherapy in Acute Myeloid Leukemia: Advancing Beyond Traditional Targets

  2. 02Hematology-Oncology

    Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.